Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -2,7 +2,7 @@
2	2	{{toc/}}
3	3	{{/box}}
4	4
5		-= Paragraph 1 =
	5	+= =
6	6
7	7	HTG Molecular is a commercial stage company that develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. Molecular profiling is the collection of information about multiple molecular targets, such as DNA and RNA, also called biomarkers, in a biological sample. Molecular profiling information has many important applications, from basic research to molecular diagnostics in personalized medicine. Its technology can be used throughout that range of applications, which is just one of its many benefits. Its focus is on clinical applications. Its primary customer segments include biopharmaceutical companies, academic research centers and molecular testing laboratories.
8	8
...	...	@@ -30,7 +30,7 @@
30	30
31	31	HTG Molecular has incurred significant losses since its inception, and HTG Molecular has never been profitable. The company incurred net losses of $5.8 million and $11.7 for the three and six months ended June 30, 2017, respectively, and $6.9 million and $13.9 for the three and six months ended June 30, 2016, respectively. As of June 30, 2017, the company had an accumulated deficit of approximately $127.3 million. As of June 30, 2017, the company had available cash and cash equivalents totaling approximately $13.4 million, and had current liabilities of approximately $10.6 million, plus an additional $10.6 million in long-term liabilities primarily attributable to its Growth Term Loan and its obligation to NuvoGen.
32	32
33		-==== Recent Developments ====
	33	+= Recent Developments =
34	34
35	35	In April 2017, the company entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., as sales agent, pursuant to which the company may offer and sell, from time to time, through Cantor Fitzgerald, shares of its common stock by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act, or the ATM Offering, and filed a prospectus supplement (File No. 333-216977) with the SEC relating to the offer and sale of up to $20,000,000 of common stock in the ATM Offering. In June 2017, the company filed an amendment to the prospectus supplement with the SEC to increase the amount of common stock that may be offered and sold in the ATM Offering to $40,000,000 in the aggregate, inclusive of the common stock previously sold in the ATM Offering prior to the date of the amendment. As of August 4, 2017, HTG Molecular has sold 3,274,341 shares of common stock in the ATM Offering at then-market prices for total gross proceeds of approximately $15.6 million. After sales commissions and other expenses payable by it in connection with the ATM Offering, its aggregate net proceeds from the ATM Offering through August 4, 2017 were approximately $14.9 million.
36	36
...	...	@@ -42,4 +42,4 @@
42	42
43	43	In July 2017, the company announced the initiation of its second development program with QML, under the Governing Agreement. Its HTG EdgeSeq technology will be used in the program to develop gene expression profiling assays for use with NGS technology in support of another pharmaceutical company’s therapeutic development and commercialization programs.
44	44
45		-m.
	45	+= References =